<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The MiCardia DYANA annuloplasty system (MiCardia Corp, Irvine, Calif) is a nitinol-based dynamic complete ring that allows modification of the septal-lateral diameter under transesophageal echocardiography guidance in the loaded beating heart after mitral valve repair </plain></SENT>
<SENT sid="1" pm="."><plain>Shape alteration is induced by radiofrequency via detachable activation wires </plain></SENT>
<SENT sid="2" pm="."><plain>This multicenter study reports the first human experience with this device </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Patients (n = 35, 67 ± 8 years) with degenerative (n = 29), functional/ischemic (n = 5), or rheumatic (n = 1) <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> underwent mitral valve repair using the new device </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed the occurrence of <z:hpo ids='HP_0011420'>death</z:hpo>, <z:hpo ids='HP_0100584'>endocarditis</z:hpo>, ring dehiscence, systolic anterior motion, <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, <z:hpo ids='HP_0100598'>pulmonary edema</z:hpo>, <z:hpo ids='HP_0001678'>heart block</z:hpo>, <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, <z:mp ids='MP_0010163'>hemolysis</z:mp>, or <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> at 30 days (primary end point) and 6 months (secondary end point) postprocedure </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> patients exhibited <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> of 2 or less early postoperatively and at 6 months follow-up </plain></SENT>
<SENT sid="6" pm="."><plain>In 29 patients, the initial mitral valve repair result was satisfactory and no ring activation was required </plain></SENT>
<SENT sid="7" pm="."><plain>In 6 patients, the nitinol-based ring was deformed intraoperatively postrepair with further improvement of <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> cases (preactivation: 0.9 ± 0.2, postactivation: 0.2 ± 0.3; P = .001) </plain></SENT>
<SENT sid="8" pm="."><plain>One <z:hpo ids='HP_0011420'>death</z:hpo> (2.9%, multisystem organ failure, non-device related), 2 <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> (5.7%), and 1 <z:hpo ids='HP_0001678'>heart block</z:hpo> (2.9%) occurred, <z:hpo ids='HP_0000001'>all</z:hpo> in the first 30 days after surgery </plain></SENT>
<SENT sid="9" pm="."><plain>No additional major adverse clinical events occurred later than 1 month postprocedure (total observed major adverse clinical event rate 11.5%) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The implantation of the new dynamic annuloplasty ring allows for safe mitral valve repair </plain></SENT>
<SENT sid="11" pm="."><plain>The option of postrepair modification of the septal-lateral diameter by radiofrequency may further optimize repair results </plain></SENT>
</text></document>